Chemotherapy Resistance and Sensitivity Testing in Lung Tumors
The purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. The results of this screening will not influence the patients treatment.
Checked against the public recordLast updated Apr 27, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Marshall University
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * suspected or confirmed diagnosis of lung cancer * undergoing a fine needle aspiration, core biopsy, or excisional biopsy for diagnosis. * Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease * Patient must be at least 18 years of age * Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database. Exclusion Criteria: * Patient pathology shows benign pathology for sample submitted * Patient is not indicated to receive chemotherapy for their disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cabell Huntington HospitalHuntington, West Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 27, 2016. Always confirm current availability with the study team.